 Neuromyelitis Optica
"Neuromyelitis Optica" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A syndrome characterized by acute OPTIC NEURITIS; MYELITIS, TRANSVERSE; demyelinating and/or necrotizing lesions in the OPTIC NERVES and SPINAL CORD; and presence of specific autoantibodies to AQUAPORIN 4.
| Descriptor ID |
D009471
|
| MeSH Number(s) |
C10.114.375.600.500 C10.114.375.800 C10.292.700.550.500 C10.314.350.600.500 C10.314.350.800 C11.640.576.695 C20.111.258.250.550.500 C20.111.258.250.775
|
| Concept/Terms |
Neuromyelitis Optica- Neuromyelitis Optica
- NMO Spectrum Disorder
- NMO Spectrum Disorders
- Neuromyelitis Optica (NMO) Spectrum Disorder
- Neuromyelitis Optica Spectrum Disorders
- Neuromyelitis Optica (NMO) Spectrum Disorders
- Devic Neuromyelitis Optica
- Devic Neuromyelitis Opticas
- Neuromyelitis Optica, Devic
- Neuromyelitis Opticas, Devic
- Devic Disease
- Disease, Devic
- Devic Syndrome
- Syndrome, Devic
- Devic's Syndrome
- Devics Syndrome
- Syndrome, Devic's
- Devic's Neuromyelitis Optica
- Devics Neuromyelitis Optica
- Neuromyelitis Optica, Devic's
- Neuromyelitis Optica Spectrum Disorder
- Devic's Disease
- Devics Disease
- Disease, Devic's
|
Below are MeSH descriptors whose meaning is more general than "Neuromyelitis Optica".
Below are MeSH descriptors whose meaning is more specific than "Neuromyelitis Optica".
This graph shows the total number of publications written about "Neuromyelitis Optica" by people in this website by year, and whether "Neuromyelitis Optica" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 2 | 0 | 2 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 7 | 1 | 8 | | 2012 | 9 | 0 | 9 | | 2013 | 5 | 1 | 6 | | 2014 | 5 | 0 | 5 | | 2015 | 6 | 0 | 6 | | 2016 | 6 | 0 | 6 | | 2017 | 4 | 3 | 7 | | 2018 | 1 | 0 | 1 | | 2019 | 6 | 0 | 6 | | 2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Neuromyelitis Optica" by people in Profiles.
-
Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, Yang CS, Jia D, Zhang TX, Yuan M, Feng Y, Yang L, Lu W, Yu C, Bennett JL, Shi FD. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020 05; 19(5):391-401.
-
Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, Gianella-Borradori A, Garren H, Weinshenker BG. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020 05; 19(5):402-412.
-
Duan T, Tradtrantip L, Phuan PW, Bennett JL, Verkman AS. Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. Neuropharmacology. 2020 01 01; 162:107827.
-
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 10 12; 394(10206):1352-1363.
-
Cook LJ, Rose JW, Alvey JS, Jolley AM, Kuhn R, Marron B, Pederson M, Enriquez R, Yearley J, McKechnie S, Han MH, Tomczak AJ, Levy M, Mealy MA, Coleman J, Bennett JL, Johnson R, Barnes-Garcia M, Traboulsee AL, Carruthers RL, Lee LE, Schubert JJ, McMullen K, Kister I, Rimler Z, Reid A, Sicotte NL, Planchon SM, Cohen JA, Ivancic D, Sedlak JL, Sand IK, Repovic P, Amezcua L, Pruitt A, Amundson E, Chitnis T, Mullin DS, Klawiter EC, Russo AW, Riley CS, Onomichi KB, Levine L, Nelson KE, Nealon NM, Engel C, Kruse-Hoyer M, Marcille M, Tornes L, Rumpf A, Greer A, Kenneally Behne M, Rodriguez RR, Behne DW, Blackway DW, Coords B, Blaschke TF, Sheard J, Smith TJ, Behne JM, Yeaman MR. Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD. Neurol Neuroimmunol Neuroinflamm. 2019 09; 6(5):e583.
-
Cotzomi E, Stathopoulos P, Lee CS, Ritchie AM, Soltys JN, Delmotte FR, Oe T, Sng J, Jiang R, Ma AK, Vander Heiden JA, Kleinstein SH, Levy M, Bennett JL, Meffre E, O'Connor KC. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain. 2019 06 01; 142(6):1598-1615.
-
Soltys J, Liu Y, Ritchie A, Wemlinger S, Schaller K, Schumann H, Owens GP, Bennett JL. Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica. J Clin Invest. 2019 04 08; 129(5):2000-2013.
-
Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, Weinshenker BG, Shosha E, Lucchinetti CF, Fryer JP, Lopez-Chiriboga AS, Chen JC, Jitprapaikulsan J, McKeon A, Gadoth A, Keegan BM, Tillema JM, Naddaf E, Patterson MC, Messacar K, Tyler KL, Flanagan EP. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurol. 2019 03 01; 76(3):301-309.
-
Liu Y, Given KS, Owens GP, Macklin WB, Bennett JL. Distinct patterns of glia repair and remyelination in antibody-mediated demyelination models of multiple sclerosis and neuromyelitis optica. Glia. 2018 12; 66(12):2575-2588.
-
Wang KY, Chetta J, Bains P, Balzer A, Lincoln J, Uribe T, Lincoln CM. Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review. Br J Radiol. 2018 Jun; 91(1086):20170690.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|